

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing:

10 February 2000 (10.02.00)

International application No.:

PCT/JP99/04015

Applicant's or agent's file reference:

2535WOOP

International filing date:

27 July 1999 (27.07.99)

Priority date:

28 July 1998 (28.07.98)

Applicant:

SHIMIZU, Toshihiro et al

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International preliminary Examining Authority on:

02 December 1999 (02.12.99)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

BEST AVAILABLE COPY

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

15
D 13 APR 2000

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT 16C3

(PCT Article 36 and Rule 70) 09/403429

Applicant's or agent's file reference JHL/G05610PC	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/JP99/04015	International filing date (day/month/year) 27/07/1999	Priority date (day/month/year) 28/07/1998
International Patent Classification (IPC) or national classification and IPC A61K9/20		
Applicant TAKEDA CHEMICAL INDUSTRIES, LTD. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 5 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 02/12/1999	Date of completion of this report 10.04.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Vayssié, S Telephone No. +49 89 2399 8635 

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/JP99/04015

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-42 as originally filed

Claims, No.:

1-19 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-19
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-19
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-19
	No:	Claims	

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/JP99/04015

2. Citations and explanations

see separate sheet

Section V: Reasoned Statement

a) Documents of the State of the Art

Reference is made to the following document:

D1: EP-A-0 839 526 (TAKEDA CHEMICAL INDUSTRIES, LTD) 6 May 1998 (1998-05-06)

b) Industrial Applicability

All the claims fulfill the requirements of Article 33(4) PCT.

c) Novelty and Inventive Step

Claims 1-19

Novelty and Inventive Step of independent Claim 1

As far as the independent product Claim 1 is concerned, the closest state of the art is considered to be D1. D1 discloses (see comparative example 3) a rapidly disintegrable solid preparation comprising meclizine HCl and scopolamine HBr as active ingredients, erythritol and mannitol as sugars and a low substituted hydroxypropylcellulose.

Therefore, the subject-matter of the invention according to Claim 1 differs from the state of the art in that the low substituted hydroxypropylcellulose has 5 % to less than 7 % by weight hydroxypropoxyl groups. Disclosed in D1 is neither the degree of substitution of the cellulose, nor the origin of this cellulose (the information on page 4, lines 44-45 relates to the composition of the invention).

Therefore, independent Claim 1 fulfills the requirements for novelty of Article 33(2) PCT.

The technical problem solved by the invention was thus to provide an orally disintegrable solid preparation with better taste, good roughness and strength. Due to the choice of the unique low substituted hydroxypropylcellulose in the specific range $5\% \leq$ hydroxypropoxyl group content $< 7\%$, enhanced dissolution properties and good taste are achieved (see especially table 1).

In order to solve this problem and in the absence of further instructions, the skilled person of the art

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/JP99/04015

would not have found in the state of the art any incentive to modify the composition according to D1 in order to obtain the invention according to Claim 1.

With respect to the documents known to the International Examining Authority, inventive step of the subject-matter of independent Claim 1 may therefore be acknowledged according to Article 33(3) PCT.

Consequently, the subject-matter of dependent Claims 2-17 and of use and method Claims 18-19 also fulfills the requirements of Article 33(2)(3) PCT.

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 2535W00P	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/JP 99/ 04015	International filing date (day/month/year) 27/07/1999	(Earliest) Priority Date (day/month/year) 28/07/1998
Applicant TAKEDA CHEMICAL INDUSTRIES, LTD. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 2 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

(57) [Abstract]

[Construction] In a composition of a tablet (referred to as rapidly disintegrating tablet) which is rapidly disintegrated by saliva (small amount of water) in oral cavity, a rapidly disintegrating tablet, which comprises a mixture of slightly substituted hydroxypropylcellulose as a disintegrating agent, crystalline cellulose as an excipient, and lubricant, wherein an incorporation ratio of slightly substituted propylcellulose and crystalline cellulose is 1:2.3 to 1:9.

[Effects] The aforementioned rapidly disintegrating tablet can provide a tablet which has a disintegrating time of 70 seconds or shorter in a disintegrating test using a small-type laboratory dish and rapidly disintegrated in a few seconds by saliva (small amount of water) in oral cavity. As a result, senior having no chewing ability can take the tablet, and one can take the tablet without water.

M.H

5000

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 9/20	A1	(11) International Publication Number: WO 00/06126 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/JP99/04015 (22) International Filing Date: 27 July 1999 (27.07.99) (30) Priority Data: 10/213049 28 July 1998 (28.07.98) JP (71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): SHIMIZU, Toshihiro [JP/JP]; 5-1-608, Kitano 6-chome, Itami-shi, Hyogo 664-0007 (JP). SUGAYA, Masae [JP/JP]; 1-8-406, Uho- cho, Ikeda-shi, Osaka 563-0042 (JP). NAKANO, Yoshinori [JP/JP]; 7-12-302, Hirai 4-chome, Takarazuka-shi, Hyogo 665-0816 (JP). (74) Agents: ASAHINA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-0024 (JP).		(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: RAPIDLY DISINTEGRABLE SOLID PREPARATION (57) Abstract A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTION

Rapidly Disintegrable Solid Preparation

5 Technical Field

The present invention relates to a solid preparation having fast disintegrability in the oral cavity with the existence of saliva, in a little water, or in the stomach particularly a rapidly disintegrable solid preparation which is useful as an orally disintegrable solid preparation.

10

Background Art

It has been desired to develop an orally disintegrable solid preparation which can be easily administered to elders or children without water. As background arts which disclose such a preparation, for example, there are the following background arts.

15 JP-A-9-48726 discloses an orally rapidly disintegrable preparation produced by wetting in a moldable way on humidifying. It comprises a drug and a material which can retain the shape after molding and drying. As such materials, a sugar, sugar alcohol and a water-soluble polymer material are exemplified.

20 JP-A-9-71523 discloses a tablet containing a drug, crystalline cellulose, a low-substituted hydroxypropylcellulose and a lubricant. It has fast disintegrability in the oral cavity.

EP-A 839526 discloses a solid pharmaceutical preparation containing a pharmacologically active ingredient, erythritol, crystalline cellulose and a disintegrator.

25 However, these background arts have not described (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group of the present invention.

Disclosure of Invention

There has been desired the development of a rapidly disintegrable solid preparation having fast disintegrability in the existence of saliva in the oral cavity, in a little water or in the stomach, having suitable strength (hardness) so that it may not be damaged through production processes and distribution, and further having no roughness.

5 The present invention relates to:

(1) a rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group;

10 (2) the preparation of the above (1), which is an orally rapidly disintegrable solid preparation;

(3) the preparation of the above (1) or (2), which is a tablet;

(4) the preparation of the above (1), wherein the sugar is a sugar alcohol;

15 (5) the preparation of the above (4), wherein the sugar alcohol is mannitol or erythritol;

(6) the preparation of the above (1), wherein the sugar is comprised in an amount of 5 to 97 parts by weight per 100 parts by weight of the solid preparation;

20 (7) the preparation of the above (1), wherein the low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group is used in an amount of 3 to 50 parts by weight per 100 parts by weight of the solid preparation;

(8) the preparation of the above (1), wherein the pharmacologically active ingredient is lansoprazole;

25 (9) the preparation of the above (1), wherein the pharmacologically active ingredient is voglibose;

(10) the preparation of the above (1), wherein the pharmacologically active ingredient is manidipine hydrochloride;

(11) the preparation of the above (1), wherein the pharmacologically active ingredient is pioglitazone hydrochloride;

(12) the preparation of the above (1), wherein the pharmacologically active ingredient is candesartan cilexetil;

(13) the preparation of the above (3) which comprises fine granules;

(14) the preparation of the above (13), wherein the pharmacologically active ingredient is comprised in the fine granules.

(15) the preparation of the above (14), wherein (i) a sugar and (ii) a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group are comprised in the solid preparation separately from the fine granules;

(16) the preparation of the above (15), wherein the sugar is in an amount of 5 to 97 parts by weight per 100 parts by weight of the rest of the solid preparation other than the fine granules;

(17) the preparation of the above (15), wherein the low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group is in an amount of 3 to 50 parts by weight per 100 parts by weight of the rest of the solid preparation other than the fine granules;

(18) use of a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group for producing a rapidly disintegrable solid preparation comprising a pharmacologically active ingredient and a sugar; and

(19) a method for improving fast disintegrability of a solid preparation comprising a pharmacologically active ingredient and a sugar, which is characterized in that a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group is contained therein.

1) Pharmacologically active ingredient

The pharmacologically active ingredients used in the present invention are in any condition such as solid, powdery, crystalline, oily and solution conditions. As such pharmacologically active ingredients, for example, one or more ingredient(s) selected

from the group comprising nourishing and cordial agents, antipyretic-anodyne-anti-inflammatory drugs, psychotropics, antianxiety drugs, antidepressants, hypnotic-sedative drugs, spasmolytics, central nervous system drugs, brain metabolism ameliorating agents, brain circulation ameliorating agents, antiepileptics, sympathomimetics, gastrointestinal
5 agents, antacids, antiulcer agents, antitussive-expectorants, antiemetics, respiratory accelerators, bronchodilators, antiallergic drugs, dental buccal drugs, antihistamines, cardiotonics, antiarrhythmic drugs, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, peripheral vasodilators, antihyperlipidemic agents, cholagogues, antibiotics, chemotherapeutic drugs, antidiabetic agents, drugs for osteoporosis,
10 antirheumatism agents, skeletal muscle relaxants, antivertigos, hormones, alkaloid narcotics, sulfa drugs, arthrifuges, blood coagulation inhibitors, antitumor agents, drugs for Alzheimer's disease and the like are exemplified.

As the nourishing and cordial agents, for instance, vitamins such as vitamin A, vitamin D, vitamin E (such as d- α -tocopherol acetate and the like), vitamin B₁ (such as
15 dibenzoylthiamine, fursultiamine hydrochloride and the like), vitamin B₂ (such as riboflavin butyrate and the like), vitamin B₆ (such as pyridoxine hydrochloride and the like), vitamin C (such as ascorbic acid, sodium L-ascorbate and the like) and vitamin B₁₂ (such as hydroxocobalamin acetate, cyanocobalamin and the like); minerals such as calcium, magnesium, iron and the like; proteins, amino acids, oligosaccharides, crude
20 drugs and the like are exemplified.

As the antipyretic-anodyne-antiinflammatory drugs, for instance, aspirin, acetaminophen, ethenzamide, ibuprofen, diphenhydramine hydrochloride, dl-chlorpheniramine maleate, dihydrocodeine phosphate, noscapine, methylephedrine hydrochloride, phenylpropanolamine hydrochloride, caffeine, anhydrous caffeine,
25 serrapeptase, lysozyme chloride, tolfenamic acid, mefenamic acid, sodium diclofenac, flufenamic acid, salicylamide, aminopyrine, ketoprofen, indometacin, bucolome, pentazocine and the like are exemplified.

As the antipsychotics, for instance, chlorpromazine, reserpine and the like are exemplified.

As the antianxiety drugs, for instance, alprazolam, chlordiazepoxide, diazepam and the like are exemplified.

As the antidepressants, for instance, imipramine, maprotiline hydrochloride, amphetamine and the like are exemplified.

5 As the hypnotic-sedative drugs, for instance, estazolam, nitrazepam, diazepam, perlapine, sodium phenobarbital and the like are exemplified.

As the spasmolytics, for instance, scopolamine hydrobromide, diphenhydramine hydrochloride, papaverine hydrochloride and the like are exemplified.

10 As the central nervous system drugs, for instance, citicoline and the like are exemplified.

As the brain metabolism ameliorating agents, for instance, meclofenoxate hydrochloride and the like are exemplified.

As the brain circulation ameliorating agents, for instance, vinpocetine and the like are exemplified.

15 As the antiepileptics, for instance, phenytoin, carbamazepine and the like are exemplified.

As the sympathomimetics, for instance, isoproterenol hydrochloride and the like are exemplified.

20 As the gastrointestinal agents, for instance, stomachic-digestives such as diastase, saccharated pepsin, scopolia extract, cellulase AP3, lipase AP and cinnamon oil; agents for intestinal disorders such as berberine chloride, resistant lactic acid bacterium, Lactobacillus bifidus and the like are exemplified.

25 As the antacids, for instance, magnesium carbonate, sodium hydrogen-carbonate, magnesium aluminometasilicate, synthetic hydrotalcite, precipitated calcium carbonate, magnesium oxide and the like are exemplified.

As the antiulcer agents, for instance, lansoprazole, omeprazole, rabeprazole, pantoprazole, famotidine, cimetidine, ranitidine hydrochloride and the like are exemplified.

As the antitussive-expectorants, for instance, chloperastine hydrochloride,

dextromethorphan hydrobromide, theophylline, potassium guaiacolsulfonate, guaiafenesin, codeine phosphate and the like are exemplified.

As the antiemetics, for instance, difenidol hydrochloride, metoclopramide and the like are exemplified.

5 As the respiratory accelerators, for instance, levallorphan tartrate and the like are exemplified.

As the bronchodilators, for instance, theophylline, salbutanol sulfate and the like are exemplified.

10 As the antiallergic drugs, for instance, amlexanox, seratrovast and the like are exemplified.

As the dental buccal drugs, for instance, oxytetracycline, triamcinolone acetate, chlorhexidine hydrochloride, lidocaine and the like are exemplified.

15 As the antihistamines, for instance, diphenhydramine hydrochloride, promethazine, isothipendyl hydrochloride, dl-chlorpheniramine maleate and the like are exemplified.

As the cardiotonics, for instance, caffeine, digoxin and the like are exemplified.

As the antiarrhythmic drugs, for instance, procainamide hydrochloride, propranolol hydrochloride, pindolol and the like are exemplified.

20 As the diuretics, for instance, isosorbide, furosemide, thiazides such as HCTZ and the like are exemplified.

As the antihypertensive agents, for instance, delapril hydrochloride, captopril, hexamethonium bromide, hydrazine hydrochloride, labetalol hydrochloride, manidipine hydrochloride, candesartan cilexetil, methyldopa, losartan, valsartan, eprosartan, irbesartan, tasosartan, telmisartan, and the like are exemplified.

25 As the vasoconstrictors, for instance, phenylephrine hydrochloride and the like are exemplified.

As the coronary vasodilators, for instance, carbocromen hydrochloride, molsidomine, verapamil hydrochloride and the like are exemplified.

As the peripheral vasodilators, for instance, cinnarizine and the like are

exemplified.

As the antihypolipidemic agents, for instance, sodium cerivastatin, simvastatin, sodium pravastatin and the like are exemplified.

5 As the cholagogues, for instance, dehydrocholic acid, trepibutone and the like are exemplified.

As the antibiotics, for instance, cepheems such as cefalexin, cefaclor, amoxicillin, pivmecillinam hydrochloride, cefotiam hexetyl hydrochloride, cefadroxil, cefixime, cefditoren pivoxil, ceftaram pivoxyl, cefpodoxime proxetil, cefotiam dihydrochloride, ceftazopran hydrochloride, cefmenoxime hemihydrochloride, sodium
10 cefsulodin; synthetic antibacterial agents such as ampicillin, ciclacillin, sodium sulbenicillin, nalidixic acid and enoxacin; monobactams such as sodium carumonam; penems; carbapenems and the like are exemplified.

As the chemotherapeutic drugs, for instance, sulfamethizole, sulfamethizole hydrochloride, thiazosulfone and the like are exemplified.

15 As the antidiabetic agents, for instance, tolbutamide, voglibose, pioglitazone hydrochloride, glibenclamide, troglitazone, rosiglitazone maleate, acarbose, miglitol, emigilate and the like are exemplified.

As the drugs for osteoporosis, for instance, ipriflavone and the like are exemplified.

20 As the skeletal muscle relaxants, for instance, methocarbamol and the like are exemplified.

As the antivertigos, for instance, meclizine hydrochloride, dimenhydrinate and the like are exemplified.

25 As the antirheumatism agents, for instance, methotrexate, bucillamine, and the like are exemplified.

As the hormones, for instance, sodium liothyronine, dexamethasone sodium phosphate, prednisolone, oxendolone, leuporelin acetate and the like are exemplified.

As the alkaloid narcotics, for instance, opium, morphine hydrochloride, ipecac, oxycodone hydrochloride, opium alkaloids hydrochlorides, cocaine hydrochloride and the

like are exemplified.

As the sulfa drugs, for instance, sulfamine, sulfisomidine, sulfamethizole and the like are exemplified.

As the arthrifuges, for instance, allopurinol, colchicine and the like are
5 exemplified.

As the blood coagulation inhibitors, for instance, dicoumarol and the like are exemplified.

As the antitumor agents, for instance, 5-fluorouracil, uracil, mitomycin and the like are exemplified.

As the drugs for Alzheimer's disease, for instance, idebenone, vinpocetine and the like are exemplified.

Among the above pharmacologically active ingredients, nourishing and cordial agents, antipyretic-anodyne-antiinflammatory drugs, hypnotic-sedative drugs, central nervous system drugs, gastrointestinal agents, antiulcer agents, antitussive-expectorants,
15 antiallergic drugs, antiarrhythmic drugs, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, antihypolipidemic agents, antidiabetic agents, drugs for osteoporosis, skeletal muscle relaxants, antivertigos and the like are preferably used.

In the present invention, the pharmacologically active ingredients preferably
20 used are antiulcer agents such as lansoprazole; antidiabetic agents such as voglibose and pioglitazone hydrochloride; and antihypertensive agents such as manidipine hydrochloride and candesartan cilexetil and the like are exemplified.

Two or more pharmacologically active ingredients can be optionally used in an admixture in a rapidly disintegrable solid preparation of this invention.

25 The pharmacologically active ingredient is optionally diluted by the diluents generally used in the fields of medical treatment and food. In addition, it is optionally treated for the purpose of masking the bitterness of the pharmacologically active ingredient.

The above pharmacologically active ingredient is used in an amount of, for

example, 0.01 to 70 parts by weight, preferably 0.02 to 50 parts by weight, more preferably 0.05 to 30 parts by weight, per 100 parts by weight of the solid preparation.

2) Sugar

5 As the sugars used in the present invention, for example, sugar, starch sugar, lactose, honey and sugar alcohol are exemplified. Such sugars are optionally used in an admixture thereof with suitable ratio.

 As the sugar, for example, sucrose, coupling sugar, fructo-oligosaccharide, palatinose are exemplified.

10 As the starch sugar, for example, glucose, maltose, powdered sugar, starch syrup, fructose and fruit sugar and the like are exemplified.

 As the lactose, for example, lactose, isomerized lactose (lactulose), reduced lactose (lactitol) and the like are exemplified.

 As the honey, various kinds of honey which are generally edible are
15 exemplified.

 As the sugar alcohol, for example, sorbitol, mannitol, maltitol, reduced starch saccharide, xylitol, reduced paratinose, erythritol, and the like are exemplified. As erythritol is optionally one used which is produced by fermentation using glucose as a starting material with yeast in general and has at most 50 mesh of the particle size. Such
20 erythritol is commercially available [for example, from Nikken Chemicals Co., Ltd. (Japan)].

 The above sugars are preferably water-soluble sugars. The water-soluble sugars mean any water-soluble sugars which need at most 30 ml of water when 1 g of sugar is added into water and then dissolved within 30 minutes at 20°C by strongly
25 shaking every 5 minutes for 30 seconds.

 In the present invention, the sugar is preferably the sugar alcohol, more preferably mannitol or erythritol.

 In order to obtain sufficient strength of the preparation and sufficiently fast disintegrability, the sugar is used in an amount of 5 to 97 parts by weight, preferably 10 to

90 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. On the other hand, the sugar is used in an amount of 5 to 97 parts by weight, preferably 10 to 90 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.

For example, mannitol or erythritol is usually used in an amount of 5 to 90 weight %, preferably 10 to 80 weight %, more preferably 20 to 80 weight %, especially preferably 50 to 80 weight % relative to the whole solid preparation in case of the solid preparation not comprising fine granules. On the other hand, mannitol or erythritol is usually used in an amount of 5 to 90 weight %, preferably 10 to 80 weight %, more preferably 20 to 80 weight %, especially preferably 50 to 80 weight % relative to the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.

3) Low-substituted Hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group (L-HPC)

3-1) Production of L-HPC

The "low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group (hereinafter, optionally referred to L-HPC)" used in the present invention can be produced in accordance with well-known methods, for example, methods described in JP-B-57-53100 or its analogous methods thereof.

At first, alkaline cellulose containing free alkaline and propylene oxide are reacted to obtain the crude low-substituted hydroxypropylcellulose containing free alkaline.

Concretely, for example, raw material pulp such as wood pulp and cotton leader is immersed in 10 to 50 % concentration of aqueous solution of sodium hydroxide, and pressed to obtain the alkaline cellulose of which NaOH/cellulose ratio is 0.1 to 1.2 (ratio by weight). Next, the crude low-substituted hydroxypropylcellulose containing free

alkaline is obtained by reacting the resulting alkaline cellulose and propylene oxide with stirring at 20 to 90°C for 2 to 8 hours. Propylene oxide is used in an amount so that the content of hydroxypropoxyl group in the desired low-substituted hydroxypropylcellulose can be 5% or more by weight to less than 7 % by weight.

5 The crude low-substituted hydroxypropylcellulose containing free alkaline is dispersed in water or hot water containing 5 to 80 % of acid which is need to neutralize the all amount of alkaline, and a part of the crude low-substituted hydroxypropylcellulose containing free alkaline is dissolved therein. Further, acid is added to neutralize the remained alkaline.

10 After the neutralization, processes such as drainage, drying and grinding are performed in accordance with the conventional method to obtain the desired low-substituted hydroxypropylcellulose.

3-2) Property of L-HPC

15 The particle diameter of L-HPC used in the present invention is, for example, 5 to 60 μm as average particle diameter. Preferably, it is 10 to 40 μm as average particle diameter.

 In the above ranges, in case that L-HPC having relatively large particle diameter (for example, L-HPC having 26 to 40 μm of average particle diameter) is used, a
20 pharmaceutical preparation being superior in disintegrability can be produced. On the other hand, in case that L-HPC having relatively small particle diameter (for example, L-HPC having 10 to 25 μm of average particle diameter) is used, the pharmaceutical preparation being superior in strength of the preparation can be produced.

 Accordingly, the particle diameter of L-HPC can be suitably selected according
25 to the character of the desired pharmaceutical preparation.

 In order to obtain sufficient strength of the preparation and sufficiently fast disintegrability, the L-HPC in the present invention is used in an amount of 3 to 50 parts by weight, preferably 5 to 40 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. On the other

hand, the L-HPC in the present invention is used in an amount of 3 to 50 parts by weight, preferably 5 to 40 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.

- 5 As mentioned above, by using L-HPC, it becomes possible to improve fast disintegrability, particularly the orally fast disintegrability, of the solid preparation containing the pharmacologically active ingredient and the sugar.

4) Dosage Forms

- 10 As the dosage form of the rapidly disintegrable solid preparation of the present invention, for example, tablet, granule, fine granule and the like, preferably tablet is exemplified. Among rapidly disintegrable tablets such as an orally disintegrable tablet and a tablet disintegrable in water, the orally disintegrable tablet is preferable.

15 5) Other Ingredients

- Unless fast disintegrability (particularly, fast disintegrability in the oral cavity) or strength of the preparation is interfered with, the rapidly disintegrable solid preparation of the present invention may further contain a variety of additives which are commonly used in the manufacture of preparations in general dosage forms. Amount of such
20 additives to be used is one commonly used in the manufacture of preparations in general dosage forms. As such additives, for example, binders, acids, foaming agents, artificial sweeteners, flavorants, lubricants, colorants, stabilizers, excipients, disintegrators and the like are exemplified.

- As the above binders, for example, hydroxypropylcellulose,
25 hydroxypropylmethylcellulose, crystalline cellulose, pregelatinized starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan and the like are exemplified. These two or more binders can be used in an admixture in a given ratio. The use of crystalline cellulose as the binder provides the solid preparation which exhibits more excellent strength of the preparation while retaining excellent fast disintegrability in the

oral cavity. As the crystalline cellulose, microcrystalline cellulose is also included. The "crystalline cellulose" includes a refined one having partially α -cellulose depolymerization. As crystalline cellulose, for example, CEOLUS KG 801, Avicel PH 101, Avicel PH 102, Avicel PH 301, Avicel PH 302, Avicel RC-A591 NF (crystalline
5 cellulose • carmellose sodium), Avicel RC-591 (crystalline cellulose • carmellose sodium) and the like are concretely exemplified. Among them, CEOLUS KG 801 referred to as highly moldable crystalline cellulose is preferably used. Such crystalline celluloses are optionally used in an admixture thereof with suitable ratio. Such crystalline celluloses can be commercially available (manufactured by Asahi Chemical
10 Industry Co., Ltd. (Japan)). The crystalline cellulose is used in an amount of, for example, 1 to 50 parts by weight, preferably 2 to 40 parts by weight, more preferably 2 to 20 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. Likewise, the crystalline cellulose is used in an amount of, for example, 1 to 50 parts by weight, preferably 2 to 40 parts by weight,
15 more preferably 2 to 20 parts by weight, per 100 parts by weight of the solid preparation apart from fine granules in case of the solid preparation comprising fine granules.

As the acids, for example, citric acid, tartaric acid, malic acid and the like are exemplified.

As the foaming agents, for example, sodium bicarbonate and the like are
20 exemplified.

As the artificial sweeteners, for example, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin and the like are exemplified.

As the flavorants, for example, lemon, lemon lime, orange, mentol, strawberry and the like are exemplified.

25 As the lubricants, for example, magnesium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid and the like are exemplified. Use of polyethylene glycol as the lubricant provides the stable solid preparation of which the decomposition over time of the pharmacologically active ingredient is controlled. At that time, polyethylene glycol is used in an amount of, for example, 0.01 to 10 parts by weight,

preferably 0.1 to 5 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. Likewise, polyethylene glycol is used in an amount of, for example, 0.01 to 10 parts by weight, preferably 0.1 to 5 parts by weight, per 100 parts by weight of the solid preparation apart from fine granules in case of the solid preparation comprising fine granules.

As the colorants, for example, various food colorants such as Food Yellow No. 5, Food Red No.2, Food Blue No. 2 and the like; food lakes, red iron oxide and the like are exemplified.

As the stabilizers, for example, a basic substance in the case of the basic pharmacologically active ingredient and an acidic substance in the case of the acidic pharmacologically active ingredient are exemplified.

As the excipients, for example, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light silicic anhydride, titanium oxide and the like are exemplified.

As the disintegrators, for example, disintegrators called super disintegrators such as crospovidone [manufactured by ISP Inc. (U.S.A.), BASF (Germany)], croscarmellose sodium [FMC-Asahi Chemical Industry Co., Ltd. (Japan)], carmellose calcium [Gotoku Chemical (Yakuhin), (Japan)]; hydroxypropylcellulose; low-substituted hydroxypropylcellulose; carboxymethylstarch sodium [Matsutani Chemical Co., Ltd. (Japan)]; corn starch and the like are exemplified. Among them, crospovidone is preferably used. Such two or more disintegrators are optionally used in an admixture thereof with suitable ratio.

As crospovidone, any cross-linked homopolymer such as 1-ethenyl-2-pyrrolidinone homopolymer may be used, and usually crospovidone having a molecular weight of at least 1,000,000 is used. As crospovidone which is commercially available, for example, Cross-linked povidone, Kollidone CL [manufactured by BASF (Germany)], Polyplasdone XL, Polyplasdone XL-10, INF-10 [manufactured by ISP Inc., (U.S.A.)], polyvinylpolypyrrolidone, PVPP, 1-vinyl-2-pyrrolidinone homopolymer and the like are concretely exemplified.

Two or more of these disintegrants can be as a mixture in a given ratio. For

example, (i) crospovidone solely, or (ii) crospovidone and another disintegrant(s) is preferably used.

Such disintegrator is used in an amount of, for example, 0.1 to 20 parts by weight, preferably 1 to 10 parts by weight, more preferably 3 to 7 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. Likewise, such disintegrator is used in an amount of, for example, 0.1 to 20 parts by weight, preferably 1 to 10 parts by weight, more preferably 3 to 7 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.

10

5-1) Other Ingredients for Dosage Forms , especially of Acid-labile Pharmacologically Active Ingredient

In case that the pharmacologically active ingredient is an acid-labile one such as lansoprazole, omeprazole, rabeprazole, pantoprazole and the like, a basic inorganic salt is preferably incorporated to stabilize the pharmacologically active ingredient in the solid preparation.

The "basic inorganic salt" includes, for example, a basic inorganic salt of sodium, potassium, magnesium and/or calcium, preferably a basic inorganic salt of magnesium and/or calcium. Among others, preferred is a basic inorganic salt of magnesium.

20

The basic inorganic salt of sodium includes, for example, sodium carbonate, sodium hydrogencarbonate, sodium phosphate, sodium hydrogenphosphate and the like.

The basic inorganic salt of potassium includes, for example, potassium carbonate, potassium hydrogencarbonate, potassium phosphate, potassium hydrogenphosphate, potassium sodium carbonate and the like.

25

The basic inorganic salt of magnesium includes, for example, heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium metasilicate aluminate, magnesium silicate aluminate, magnesium silicate, magnesium aluminate, synthetic hydrotalcite $[\text{Mg}_6\text{Al}_2(\text{OH})_{16} \cdot \text{CO}_3 \cdot 4\text{H}_2\text{O}]$, aluminum

magnesium hydroxide [$2.5\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot x\text{H}_2\text{O}$] and the like. Among others, preferred is heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide and the like.

5 The basic inorganic salt of calcium includes, for example, precipitated calcium carbonate, calcium hydroxide, and the like.

The preferable examples of the "basic inorganic salt" are magnesium basic inorganic salt, and more preferable examples include heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, and the like.

10 Such basic inorganic salt of magnesium or calcium, and the like has a basic pH (not less than 7) when it is in the form of a 1 % aqueous solution or suspension.

Two or more of these basic inorganic salts (preferably a basic inorganic salt of magnesium, a basic inorganic salt of calcium, and the like) can be used as a mixture in a given ratio. The amount of the basic inorganic salt to be used is appropriately selected depending on the kind of the basic inorganic salt and is, for instance, 0.3 to 200 parts by weight, preferably 1 to 100 parts by weight, more preferably 10 to 50 parts by weight, especially preferably 20 to 40 parts by weight relative to the pharmacologically active ingredient.

6) Dosage Form containing Fine Granules (e.g., Tablet)

20 As was mentioned before, the rapidly disintegrable preparation of the present invention can be used in any solid dosage form such as tablet, granule, fine granule and the like. In case that it is a tablet, the tablet can contain fine granules. The fine granules may contain the pharmacologically active ingredient. These dosage forms can be prepared by a conventional method or its analogous method.

25

7) Fine Granule containing Core

The fine granule can contain a core together with or separately from the pharmacologically active ingredient. As such a core, for example, (1) a spherical granulated product comprising crystalline cellulose and lactose [e.g., a spherical

granulated product being 100 to 200 μm and comprising crystalline cellulose (3 parts) and lactose (7 parts) (Nonpareil 105 (trade name), manufactured by Freund Industrial Co., Ltd. (Japan)), a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (3 parts) and lactose (7 parts) (Nonpareil NP-7:3 (trade name), manufactured by Freund Industrial Co., Ltd. (Japan)), a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (5 parts) and lactose (5 parts) (Nonpareil NP-5:5 (trade name), manufactured by Freund Industrial Co., Ltd. (Japan)) and the like], (2) a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose [avicel SP (trade name), manufactured by Asahi Chemical Industry Co., Ltd. (Japan) and the like) and the like are exemplified.

In case that a core is used, the core is optionally coated with the pharmacologically active ingredient and the like, and further coated for masking taste or smell and/or for imparting enteric dissolubility or sustained-release property by well known methods. In this case, such a core forms a fine granule comprising the pharmacologically active ingredient. As a coating agent in this case, for example, enteric-coated polymers (e.g., cellulose acetate phthalate (CAP), methacrylate copolymer L, methacrylate copolymer LD (Eudragit L30D-55(trade name; manufactured by Rohm GmbH (Germany))), methacrylate copolymer S, hydroxypropylmethylcellulose phthalate, hydroxymethylcellulose acetate succinate, hydroxypropylmethylcellulose acetate succinate, KolliCoat MAE30DP (trade name; manufactured by BASF (Germany)), Polyquid PA-30 (trade name; manufactured by SanyoKasei (Japan)), carboxymethylethylcellulose, shellac, methacrylate copolymer [e.g., Eudragit NE30D (trade name), Eudragit RL30D (trade name), Eudragit RS30D (trade name) and the like] triethyl citrate, polyethylene glycol, acetylated monoglyceride, triacetin, castor oil, and the like), gastric dissolvable polymers (e.g., polyvinylacetal diethylaminoacetate, aminoalkyl methacrylate copolymer and the like), water-soluble polymers (e.g., hydroxypropylcellulose, hydroxypropylmethylcellulose and the like), slightly soluble polymers (e.g., ethylcellulose, aminoalkyl methacrylate copolymer RS, ethyl acrylate methyl methacrylate copolymer and the like), wax and the like are exemplified. One or

more kind(s) of coating agents are used in an admixture.

7-1) Production of Fine Granules

5 The "fine granules" in the present invention can be produced by a known granulation method.

The "granulation method" includes, for example, rolling granulation method (e.g., centrifugal rolling granulation, etc.), fluidized-bed granulation (e.g., rolling fluidized-bed granulation, fluidized granulation, etc.), stirring granulation and the like. Among others, preferred is fluidized-bed granulation method, more preferred is rolling
10 fluidized-bed granulation method.

Concrete example of the "rolling granulation method" includes a method using "CF apparatus" manufactured by Freund Industrial Co., Ltd. (Japan) and the like. Concrete examples of the "rolling fluidized-bed granulation method" include methods using "SPIR-A-FLOW", "multi plex" manufactured by Powrex Corp. (Japan), "New-
15 Marumerizer" manufactured by Fuji Paudal Co., Ltd. (Japan), and the like. The method for spraying the mixture can be suitably selected in accordance with the kind of granulator, and may be, for example, any one of a top spray method, a bottom spray method, a tangential spray method, and the like. Among others, a tangential spray method is preferred.

20 The "fine granules" in the present invention can be coated with any other ingredient including the active ingredient and the others, by a conventional coating method or its analogous method. For example, a method which comprises coating a core comprising crystalline cellulose and lactose with an acid-labile physiologically active substance is employed in case that pharmacologically active ingredient is an acid-labile
25 physiologically active substance.

For example, used is a method described in JP-A-5-92918 (coating method), which comprises coating a core comprising crystalline cellulose and lactose with an acid-labile physiologically active substance, if necessary together with a basic inorganic salt, binders, lubricants, excipients, a water-soluble polymer, etc. (hereinafter, may be

abbreviated to "coating layer"). For example, employed is a method which comprises coating a core with an acid-labile physiologically active substance and a basic inorganic salt, and then further with binders, lubricants, excipients, a water-soluble polymer, etc.

5 7-2) Property of Core for Fine Granules

The average particle diameter of the "cores" is 250 μm or less, preferably 50 to 250 μm , more preferably 100 to 250 μm , especially preferably 100 to 200 μm . The "cores" having the above average particle diameter include particles which all pass through a #50 sieve (300 μm), particles where 5 w/w % or less of the total remain on a
10 #60 sieve (250 μm), and particles where 10 w/w % or less of the total pass through a #282 sieve (53 μm). The specific volume of the "core" is 5 ml/g or less, preferably 3 ml/g or less.

Examples of the "core" include :

- (1) a spherical granulated product comprising crystalline cellulose and lactose, (2) a
15 spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (Avicel SP, manufactured by Asahi Chemical Co., Ltd. (Japan)), (3) a stirring granulated product being 50 to 250 μm and comprising lactose (9 parts) and a starch (1 part), (4) a micro particle being 250 μm or less classified as a spherical granule comprising micro crystalline cellulose described in JP-A-61-213201, (5) a processed product such as wax
20 formed to a sphere by spraying or melting granulation, (6) a processed product such as gelatin beads comprising oil component, (7) calcium silicate, (8) starch, (9) a porous particle such as chitin, cellulose, chitosan, etc, and (10) a bulk product such as granulated sugar, crystalline lactose or sodium chloride, and processed preparations thereof.
- Further, these cores may be produced in accordance with *per se* known grinding method
25 or granulation method, and sifted to prepare the particles having the desired particle diameter.

The above "spherical granulated product comprising crystalline cellulose and lactose" includes, for example (i) a spherical granulated product being 100 to 200 μm and comprising crystalline cellulose (3 parts) and lactose (7 parts) [e.g., Nonpareil 105 (70-

140) (particle diameter of 100 to 200 μm), manufactured by Freund Industrial Co., Ltd. (Japan)], (ii) a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (3 parts) and lactose (7 parts) [e.g., Nonpareil NP-7:3, manufactured by Freund Industrial Co., Ltd. (Japan)], (iii) a spherical granulated product being 100 to
5 200 μm and comprising crystalline cellulose (4.5 parts) and lactose (5.5 parts) [e.g., Nonpareil 105T (70-140) (particle diameter of 100 to 200 μm), manufactured by Freund Industrial Co., Ltd. (Japan)], (iv) a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (5 parts) and lactose (5 parts) [e.g., Nonpareil NP-5:5, manufactured by Freund Industrial Co., Ltd. (Japan)], and the like.

10 In order to produce a pharmaceutical preparation which is superior in dissolution while retaining suitable strength, the "core" includes, for example, preferably the spherical granulated product comprising crystalline cellulose and lactose, more preferably the spherical granulated material comprising crystalline cellulose and lactose and containing 50 weight % or more of lactose relative to the whole solid preparation.
15 Among others, preferred is a core comprising 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.

As the "core" employed in the present invention, preferably, there may be employed the spherical granulated product comprising crystalline cellulose and lactose, more preferably the spherical granulated product with a diameter of 100 to 200 μm and
20 comprising crystalline cellulose (4.5 parts) and lactose (5.5 parts).

The "core" may contain the physiologically active substance such as the above described pharmacologically active ingredient. Also, the "core" may not contain the physiologically active substance because the release of the physiologically active substance can be controlled by a coating layer containing the physiologically active
25 substance.

The "core" is preferably as uniform a sphere as possible, for reducing the irregularity of the coating, in addition to being a powdery core.

The ratio of the "coating layer" to the "core" can be selected within the range in which it is possible to control dissolution of the physiologically active substance and

particle size of the composition, for example, usually 50 to 400 parts by weight relative to 100 parts by weight of the core.

7-3) Coating Method of Fine Granules

5 The coating layer may be constructed by plural layers. At least one layer of the plural layers must contain the physiologically active substance. The combination of various layers such as a coating layer not containing the active ingredient, a base coating layer, and an enteric coating layer which constitute the coating layer can be suitably selected.

10 In case that the "core" is coated, for example, the above physiologically active substance and the water-soluble polymer can be employed in an admixture thereof. The admixture may be a solution or a dispersion, and can be prepared by using an organic solvent such as water or ethanol or an admixture thereof.

 The concentration of the water-soluble polymer in the admixture varies
15 according to the ratio of the physiologically active substance and the additives, and is usually 0.1 to 50 weight %, preferably 0.5 to 10 weight % relative to the whole solid preparation, in order to retain the binding strength of the physiologically active substance to the core and maintain the viscosity of the mixture so as not to reduce the workability.

 Where the coating layer comprises plural layers, the concentration of the
20 physiologically active substance in each layer may be changed successively or gradually by selecting for the content ratio or viscosity of the water-soluble polymer or by successive coating with mixtures varying in the ratio of the physiologically active substance and the other additives. In the above case, it may be coated with a mixture in which the content ratio of the water-soluble polymer is out of the range of 0.1 to 50
25 weight %, as long as the coating layer as a whole contains 0.1 to 50 weight % of the water-soluble polymer. Further, in forming the inactive coat according to known methods, the coating layer optionally comprises some layers such that the inactive layer may block each layer containing the physiologically active substance.

 Also, in case of two or more physiologically active substances not suited in the

compatibility, the core may be coated by employing each mixture together or separately.

The above coated material is dried, and passed through sieves to obtain a "composition" having uniform size. Because the form of the composition is usually according to the core, a fine granule being in the form of a rough sphere can be obtained.

- 5 As the sieve may be employed, for example a #50 circular sieve (300 μm). The composition is obtained by selecting those which pass through the #50 circular sieve.

The "fine granule" in the present invention can be produced in accordance with in the same manner as above granulation method, for example, a method which comprises coating the composition with an enteric coating layer, in order to protect the
10 physiologically active substance or to impart enteric dissolution. If necessary, the composition coated with an enteric coating layer may be further coated by a water-soluble sugar alcohol, preferably mannitol. In such case, the strength of the orally disintegrable tablet comprising fine granules is improved.

The "enteric coating layer" is preferably a layer having 20 to 70 μm , preferably
15 30 to 50 μm of thickness and coating the whole surface of the composition containing the physiologically active substance. Accordingly, the smaller particle diameter of the composition, the higher the weight % of the enteric coating layer in the whole fine granule. In the fine granule of the present invention, the "enteric coating layer" is 30 to 70 weight %, preferably 50 to 70 weight %, of the fine granule as a whole.

20 The "enteric coating layer" are optionally constructed by plural (e.g., 2 or 3) layers. For example, the used is a method which comprises coating a composition with an enteric coating layer having polyethyleneglycol, and then with an enteric coating layer having triethyl citrate, followed by being coated with an enteric coating layer having polyethyleneglycol.

25

8) Production of Rapidly Disintegrable Solid Preparation

The rapidly disintegrable solid preparation of the present invention can be produced in accordance with a conventional method or its analogous method in the field of pharmaceutical preparation. As such method, for example, a method comprising

blending the pharmacologically active ingredient, the sugar and the low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group after adding water if needed, molding, and then drying if needed is exemplified. However, the rapidly disintegrable solid preparation of the present invention can be produced also without water.

8-1) Production of Rapidly Disintegrable Tablet

For the production of the orally disintegrable tablet, a conventional molding method or its analogous method can be applied by using appropriate ingredients selected from the above-mentioned ones including the fine granules.

Preferred example of the method for the orally disintegrable tablet having the fine granules of the coated cores comprises:

- (i) coating a core comprising crystalline cellulose and lactose with a physiologically active substance and an excipient, followed by being coated with a coating layer comprising a water-soluble polymer to obtain a composition,
- (ii) coating the resultant composition with an enteric coating layer having polyethyleneglycol, and then with an enteric coating layer having triethyl citrate, and then followed by being coated by mannitol to obtain fine granule, and
- (iii) blending the resultant fine granule with an additive, followed by molding.

The molding procedure can be carried out, for instance, by tableting with a pressure of 0.5 to 3 ton/cm², preferably 1 to 2 ton/cm² by using a single-punch tableting machine [Kikusui Seisakusho (Japan)] or a rotary type tableting machine [Kikusui Seisakusho (Japan)] when a solid preparation is a tablet, especially an orally disintegrable tablet.

The drying procedure can be carried out by any techniques such as vacuum drying, fluidized-bed drying and the like used to dry the general pharmaceutical preparation.

The blending procedure can be carried out by any conventional blending techniques such as admixing, kneading, granulating and the like. The blending

procedure is carried out by using an apparatus such as Vertical Granulator VG10 [manufactured by Powrex Corp. (Japan)], Universal Kneader [manufactured by Hata Iron Works Co., Ltd. (Japan)], fluidized bed granulator LAB-1 and FD-3S [manufactured by Powrex Corp. (Japan)], centrifugal fluidized coating granulator MP-10, MP-400
5 [manufactured by Powrex Corp. (Japan)] and the like.

In the present specification, "coating" means also partial coating and adhesion or adsorption in addition to coating the whole surface of an object (e.g., core) which is to be coated.

"Spherical" means also forms having a curved surface such as forms having
10 elliptic cross sections, and forms in the shapes of eggplants and drops in addition to spheres.

"Average particle diameter" means volume based distribution median diameter (median diameter: 50% particle diameter from cumulative distribution), unless otherwise specified. It can be measured by, for example, a laser diffraction particle distribution
15 measurement method. Concretely exemplified is a method using Raiser Diffraction Analyzer, type: HEROS RODOS [trade name; manufactured by Sympatec (Germany)].

In the present invention, "fine granules" have an average particle diameter of about 400 μm or less, in order that roughness is not felt in the mouth. Preferably, the average particle diameter of the fine granules is 300 to 400 μm .

20 Aside from the average particle diameter of the above "fine granules", regarding the maximum particle size, the particle diameter is substantially 425 μm or less, and preferably substantially 400 μm or less. Preferably, the particle diameter is substantially 300 to 425 μm , more preferably 300 to 400 μm .

"Substantially" as used in the phrases of "the particle diameter is substantially
25 425 μm or less" and "the particle diameter is substantially 400 μm or less" means that the particles may include a small quantity (about 5 weight % or less) of particles whose particle diameter is out of the above described range, to include the inevitable contaminant particles.

The "composition" may contain water-soluble polymers, the above binders,

lubricants, excipients and the like in common use as pharmaceutical materials. The amount of such water-soluble polymers, binders, lubricants, and excipients is selected from amounts commonly employed in the manufacture of preparations in general dosage forms.

5 The "water-soluble polymer" includes, for example, a water-soluble polymer which is soluble in ethanol (i.e., an ethanol-soluble water-soluble polymer) such as a cellulose derivative (e.g., hydroxypropyl cellulose, which may be referred to as "HPC" hereinafter), polyvinylpyrrolidone, etc.; a water-soluble polymer which is insoluble in ethanol (i.e., an ethanol-insoluble water-soluble polymer) such as a cellulose derivative
10 (e.g., hydroxypropylmethyl cellulose, which may be referred to as "HPMC" hereinafter, methyl cellulose, carboxymethyl cellulose sodium, etc.), sodium polyacrylate, polyvinyl alcohol, sodium alginate, and guar gum, etc.

 When such water-soluble polymers are used, the dissolution of drugs (physiologically active substances) can be controlled by employing them in combination
15 with the ethanol-soluble water-soluble polymer and ethanol-insoluble water-soluble polymer or by employing them in combination with some water-soluble polymers having different viscosity.

 In the present invention, the "water-soluble polymer" is preferably, a cellulose derivative such as HPC, HPMC, and methyl cellulose, and polyvinyl alcohol. More
20 preferred is a cellulose derivative such as HPC, HPMC.

 The "HPC" contains, for example, about 53.4 to 77.5 weight %, more preferably about 60 to 70 weight %, of hydroxypropoxyl group. The viscosity of 2 weight % aqueous solution of HPC at 20 °C is usually about 1 to 150,000 cps (centipoise). As the above HPC, hydroxypropyl cellulose defined in Japanese Pharmacopoeia may be
25 employed. Hereinafter, all viscosity of HPC is a value of 2 weight % aqueous solution at 20 °C.

 The "HPMC" is a mixed ether which is connected by a methoxy group and a hydroxypropoxy group. The content of the methoxy group of HPMC is, for example, about 19 to 30 weight %. The content of the hydroxypropoxy group is, for example,

about 4 to 12 weight %. The viscosity of 2 weight % aqueous solution of HPMC at 20 °C is usually about 1 to 40,000 centistokes. As such HPMC may be employed hydroxypropylmethyl cellulose 2208 defined by Japanese Pharmacopoeia, hydroxypropylmethyl cellulose 2906 defined by Japanese Pharmacopoeia, 5 hydroxypropylmethyl cellulose 2910 defined by Japanese Pharmacopoeia, and so forth. Hydroxypropyl cellulose(s) may be employed alone or in an admixture of two or more thereof.

The content of the water-soluble polymer such as HPC and/or HPMC is usually about 0.1 to 50 weight %, preferably about 1 to 30 weight %, as against the whole 10 "composition" containing the physiologically active substance, in order to control the dissolution of the physiologically active substance in the composition containing the physiologically active substance and retain a high content of the physiologically active substance.

In the present invention, the "fine granules" may contain, for example, titanium 15 oxide as a masking agent.

The diameter of the "orally disintegrable tablet" of the present invention is about 5 to 20 mm, preferably about 7 to 15 mm, more preferably about 8 to 13 mm.

The "orally disintegrable tablet" optionally may not comprise lubricant inside the tablet.

20 When the "fine granule" of the present invention is used for a tablet except for an orally disintegrable tablet, the diameter of the tablet is about 5 to 10 mm, preferably about 5 to 8 mm. When the fine granule of the present invention is used for a capsule, the size of the capsule is preferably a #2 capsule or less.

25 9) Property of Rapidly Disintegrable Solid Preparation

The rapidly disintegrable solid preparation of the present invention thus obtained exhibits fast disintegrability or dissolubility in the oral cavity, water or stomach, and suitable strength of the preparation. Further the rapidly disintegrable solid preparation of the present invention is improved in chalky taste and has no roughness.

9-1) Disintegration Time

The orally disintegration time of the rapidly disintegrable solid preparation of the present invention (the time for healthy male or female adults to complete disintegration by buccal saliva) is usually 5 to 50 seconds, preferably 5 to 40 seconds, more preferably 5 to 35 seconds.

The disintegration time in the stomach of the rapidly disintegrable solid preparation of the present invention (the time for healthy male or female adults to complete disintegration) is shorter than that of the normal preparation such as a normal tablet.

The disintegration time of the rapidly disintegrable solid preparation of the present invention in water is usually 5 to 40 seconds, preferably 5 to 30 seconds, more preferably 5 to 25 seconds.

9-2) Strength of Preparation

The strength of the rapidly disintegrable solid preparation of the present invention (measurement with a tablet hardness tester) is usually 2 to 20 kg, preferably 4 to 15 kg.

9-3) Administration Manner

The rapidly disintegrable solid preparation of the invention is especially used for an orally disintegrable tablet and can be administered without water or together with water.

As administration methods, there are listed (1) a method of administration by dissolution or disintegration together with a little water, or without water and with saliva in the oral cavity, not to be swallowed as it is, or (2) a method of administration with water, where it is swallowed as it is. Also, the tablet may be administered dissolved or disintegrated with water.

The "orally disintegrable tablet" of the present invention is advantageously used

in (a) cases where administration without water is necessary, (b) cases of administration to a patients who have difficulty in swallowing tablets, or (c) cases of administration to the aged or to children where there is a fear of blocking the throat if it is in usual tablet form.

- 5 The rapidly disintegrable solid preparation of the present invention can be safely administered orally to mammals such as mouse, rat, rabbit, cat, dog, bovine, horse, monkey, human and the like.

9-4) Dose and Specific Embodiments

- 10 While the dosage amount of the rapidly disintegrable solid preparation varies depending on a pharmacologically active ingredient, a subject, a kind of disease and the like, the dosage amount is selected so that the dosage amount of the pharmacologically active ingredient can be an effective amount.

- 15 In case of the above (a), the orally disintegrable tablet is preferably used for antipyretic agents, analgesic agents, anti-inflammatory agents, antianxiety drugs, antitussive-expectorants, anti motion sickness agents, drugs for prevention and treatment for car-sickness, and the like.

- 20 In case of the above (b), the orally disintegrable tablet is preferably used for preventing and/or treating hypertension, hyperlipemia, diabetes, bronchial asthma, cerebrovascular diseases, and the like.

9-4-1) Lansoprazole

- 25 For instance, when lansoprazole is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of digestive ulcer (such as gastric ulcer, duodenal ulcer, anastomic ulcer, Zollinger-Ellison syndrome), gastritis, reflex esophagitis and the like; eradication of *H. pylori*; suppression of upper gastrointestinal bleeding caused by digestive ulcer, acute stress ulcer and hemorrhagic gastritis; suppression of upper gastrointestinal bleeding caused by invasive stress (such as stress caused by a large-scale

operation necessitating the following intensive management or cerebrovascular disease, head injury, failure of many organs, burn injury of a wide range which necessitate intensive care); treatment and prevention of ulcer caused by non-steroidal anti-inflammatory agent; treatment and prevention of gastric hyperacidity and ulcer caused by postoperative stress; administration before anesthesia and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 0.5 to 1500 mg/day, preferably 5 to 150 mg/day, as lansoprazole.

9-4-2) Voglibose

When voglibose is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of obesity, adiposis, lipemia, diabetes mellitus and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 0.01 to 30 mg/day, preferably 0.1 to 3 mg/day, as voglibose. The rapidly disintegrable solid preparation can be administered once a day, or 2 to 3 times separately a day.

9-4-3) Manidipine·HCl

When manidipine hydrochloride is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of circulatory system diseases such as hypertension, ischemic heart disease (e.g., angina pectori, myocardial infarction and the like), cerebral and peripheral circulatory disorders (e.g., cerebral infarction, transient ischemic attack, constriction of renal artery and the like) and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 1 to 200 mg/day, preferably 10 to 20 mg/day, as manidipine hydrochloride. The rapidly disintegrable solid preparation is usually administered once a day after breakfast.

9-4-4) Pioglitazone·HCl

When pioglitazone hydrochloride is used as the pharmacologically active

ingredient, the rapidly disintegrable solid preparation of the present invention is useful as the insulin resistance improving agent and the like, and for treatment and prevention of diabetes mellitus. The dosage amount of the preparation per an adult (body weight: 60 kg) is 7.5 to 60 mg/day, preferably 15 to 45 mg/day, as pioglitazone hydrochloride. The rapidly disintegrable solid preparation can be administered once a day, or 2 to 3 times separately a day.

9-4-5) Candesartan Cilexetil

Further, when candesartan cilexetil is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of hypertension, heart diseases, cerebral apoplexy, renal diseases and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 1 to 50 mg/day, preferably 2 to 30 mg/day, as candesartan cilexetil.

15 BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is more specifically explained by means of the following Reference Examples, Examples and Test Examples. It is to be understood that the present invention is not limited to these Examples.

Unless otherwise specifically indicated, the following "%" means % by weight.

Also, the content of hydroxypropoxyl group is measured in accordance with the methods described in Japanese Pharmacopoeia (e.g., 13th edition). The physical properties (hardness and disintegration time) of the tablets were determined by the following test methods.

(1) Hardness test

Determination was carried out with a tablet hardness tester [manufactured by Toyama Sangyo Co. Ltd. (Japan)]. The test was performed in 10 runs and mean values were shown.

(2) Oral disintegration time

Time for complete disintegration or dissolution of the tablets only by saliva in

the oral cavity was determined.

Examples

Reference Example 1

An alkaline cellulose comprising 24.1 % of NaOH, 1.7 % of Na₂CO₃, 42.9 % of
5 cellulose, 31.8 % of H₂O was obtained by immersing wood pulp in 49% aqueous solution
of sodium hydroxide and then by pressing it. A reactor was charged with 100 parts by
weight of the alkaline cellulose. Then, nitrogen gas replacement was carried out. After
the replacement, 5 parts by weight of propylene oxide was charged in the reactor and
reacted with stirring at 40°C for 1 hour, at 50°C for 1 hour and at 70°C for 1 hour to
10 provide 103 parts by weight of a reactant.

On the other hand, a kneader was charged with 2.5 parts by weight of hot water
at 65°C and 0.13 parts by weight of glacial acetic acid (40 % by weight against
equivalent for neutralization, initial neutralized acid) and therein, 1 part by weight of the
above resulting alkaline cellulose was dispersed. Then, the temperature was adjusted at
15 30°C to dissolve a part of the reactant, and 0.20 part by weight of glacial acetic acid
(remain of equivalent for neutralization, complete neutralized acid) to provide a
processed fiber product containing a part of dissolution and a part of deposit.

The resulting product was washed with hot water at 80°C, drained, dried,
ground by means of high rolling impact grinder, and sifted by means of a 100 mesh sieve
20 to provide the powder of low-substituted hydroxypropylcellulose LH-33 (content of
hydroxypropoxyl group: 5.8 % by weight, average particle diameter: 17.8 µm).

Reference Example 2

Powders of low-substituted hydroxypropylcellulose LH-23, which have a little
bigger average particle diameter (content of hydroxypropyl group: 5.7 % by weight,
25 average particle diameter: 30.8 µm) were obtained in the same manner as in Reference
Example 1.

Example 1

(1) Production of powders having a core

A centrifugal fluidized coating granulator [manufactured by Powrex Corp.

(Japan), MP-10] was charged with 900 g of Nonpareil 105 (trade name) (particle diameter: 100 to 200 μm). While the inlet air temperature and the outlet air temperature were controlled at 70°C and 30°C respectively, the Nonpareil was coated by spraying a spray liquid of the following composition prepared in advance in accordance with the tangential spray method at the spray rate of 22 g/min. Then, drying was carried out for 10 minutes. The resulting granules were sieved through a #60 circular sieve (250 μm) and a #100 circular sieve (150 μm) to provide 2186 g of powders (150 to 250 μm) having a core.

[Spray liquid]

Lansoprazole	927 g
Magnesium carbonate	309 g
Low-substituted hydroxypropylcellulose LH-32 (Content of hydroxypropyl group: 8.8 % by weight) (Average particle diameter: 17.57 μm)	154.5 g
Hydroxypropylcellulose (Type SSL)	309 g
Purified water	3955 g

10

(2) Production of film-undercoated powders having a core

A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 2040 g of the above powders having a core. While the inlet air temperature and the outlet air temperature were controlled at 75°C and 40°C respectively, an undercoating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 13 g/min. 2145 g of film-undercoated powders having a core was obtained.

15

[Undercoating liquid]

Hydroxypropylmethylcellulose (Type 2910, viscosity: 3 centistokes)	264 g
Purified water	5016 g

20 (3) Production of enteric-coated powders having a core

A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 1710 g of the above film-undercoated powders having

a core. While the inlet air temperature and the outlet air temperature were controlled at 70°C and 40°C respectively, an enteric film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 19 g/min. Then, drying was carried out for 7 minutes. The resulting granules were sieved through a #42 circular sieve (355 μm) and a #80 circular sieve (177 μm) to provide 2393 g of powders (177 to 355 μm) having a core.

[Enteric film coating liquid]

Eudragit L30D-55	5016.4 g
Eudragit NE30D	559.0 g
Triethyl citrate	333.7 g
Glyceryl monostearate	106.5 g
Polysorbate 80	34.8 g
Red iron oxide	1.8 g
Purified water	2547.1 g

(4) Production of mannitol-overcoated enteric-coated powders having a core

A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 600 g of the above enteric-coated powders having a core. While the inlet air temperature and the outlet air temperature were controlled at 65°C and 32°C respectively, a film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 11 g/min. Then, drying was carried out for 7 minutes. 617 g of overcoated enteric-coated powders having a core was obtained.

[Film coating liquid]

Mannitol	33 g
Purified water	297 g

(5) Production of mannitol granulated powders

A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 800 g of mannitol [manufactured by Merck Japan Co., Ltd.], and granulation was carried out while spraying 315 g of purified water. The granules were

dried to provide 727.3 g of granulated powders.

(6) Production of mixed powders

To 105 g of the above overcoated enteric-coated powders having a core were added 97.3 g of the above mannitol-granulated powders, 15.0 g of low-substituted hydroxypropyl cellulose LH-33 (content of hydroxypropoxyl group: 5.8 % by weight, average particle diameter: 17.8 μm), 22.5 g of crystalline cellulose [CEOLUS KG-801 (trade name), manufactured by Asahi Chemical Industry Co., Ltd. (Japan)], 7.5 g of crospovidone, 1.5 g of anhydrous citric acid, 0.45 g of aspartame and 0.75 g of magnesium stearate, which were admixed in a bag to give mixed powders.

10 (7) Production of orally disintegrable tablets

250 g of the above mixed powder was tableted by a pounder (15R, 11 mm in diameter) using a rotary type tableting machine at the tableting pressure of 1.5 ton/cm^2 to provide tablets each weighing 500 mg.

The hardness and oral disintegration time of each tablet thus obtained were 5.9 kg and 30 seconds respectively.

Example 2

(1) Production of granules having a core

A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)] was charged with 900 g of Nonpareil 105 (trade name) (particle diameter of 100 to 200 μm). With the inlet air temperature and the temperature of the loading being controlled at 65 °C and about 30 °C respectively, the Nonpareil was coated by spraying a bulk liquid of the following composition prepared in advance in accordance with the tangential spray method at a spray rate of 22 g/min. The spraying operation was stopped when the specified amount 5661 g of the bulk liquid had been sprayed, and then drying was carried out in the granulator for 8 minutes. The resulting granules were sieved through a #42 circular sieve (350 μm) and a #100 circular sieve (150 μm) to provide 2074 g of granules having a core.

Bulk liquid:

Lansoprazole	1080 g
Magnesium carbonate	360 g
Low-substituted hydroxypropyl cellulose LH-32 (hydroxypropoxyl group contents: 8.8 weight %)	180 g
Hydroxypropyl cellulose (Type SSL)	360 g
Purified water	4680 g

(2) Production of film-undercoated granules having a core

A centrifugal fluidized coating granulator [manufactured by Powrex Corp.

- 5 (Japan), MP-10 (Type 2)] was charged with 2074 g of the above granules having a core. With the inlet air temperature and the temperature of the loading being controlled at 78 °C and about 40 °C, respectively, an undercoating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min. The spraying operation was stopped when the specified amount
- 10 1980 g of the undercoating liquid had been sprayed, and then drying was carried out in the granulator for 9 minutes. The resulting granules were sieved through a #42 circular sieve (350 µm) and a #100 circular sieve (150 µm) to provide 2555 g of film-undercoated granules having a core.

15 Undercoating liquid:

Hydroxypropylmethylcellulose (Type 2910, viscosity: 3 centistokes)	252 g
Titanium oxide (TiO ₂)	108 g
Sterilized Talc (trade name) [produced by Matsumura Sangyo Co. Ltd. (Japan)]	108 g
Low-substituted hydroxypropyl cellulose LH-32 (hydroxypropoxyl group contents: 8.8 weight %)	180 g
Mannitol	252 g
Purified water	3600 g

(3) Production of enteric coated granules having a core

A centrifugal fluidized coating granulator [manufactured by Powrex Corp.

(Japan), MP-10 (Type 2)] was charged with 1320 g of the above film-undercoated

- granules having a core. With the inlet air temperature and the temperature of the loading being controlled at 80 °C and about 42 °C, respectively, an enteric film coating liquid (A) of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g /min. The specified amount
- 5 1638 g of the enteric film coating liquid had been sprayed.

Enteric film coating liquid (A):

Eudragit L30D-55	1219.2 g
Eudragit NE30D	134.4 g
Polyethylene glycol 6000	40.8 g
Glyceryl monostearate	24.0 g
Polysorbate 80	7.2 g
Ferric oxide	0.24 g
Ferric oxide (yellow)	0.24 g
Citric acid anhydrous	0.48 g
Purified water	1693 g

- Following this, with the inlet air temperature and the temperature of the loading
- 10 being controlled at 76 °C and about 42 °C, respectively, an enteric film coating liquid (B) of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g /min. The specified amount 6552 g of the enteric film coating liquid had been sprayed.

15 Enteric film coating liquid (B):

Eudragit L30D-55	4032 g
Eudragit NE30D	447.8 g
Triethyl citrate	269.3 g
Glyceryl monostearate	86.4 g
Polysorbate 80	25.9 g
Ferric oxide	0.86 g
Ferric oxide (yellow)	0.86 g
Citric acid anhydrous	0.72 g
Purified water	2624 g

Following this, with the inlet air temperature and the temperature of the loading being controlled at 80 °C and about 42 °C, respectively, an enteric film coating liquid (A) of the above mentioned composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g /min. The specified amount 819 g of the enteric film coating liquid had been sprayed.

(4) Production of enteric coated and mannitol coated granules having a core

Following (3), with the inlet air temperature and the temperature of the loading being controlled at 85 °C and about 35 °C, respectively, an film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g /min. using a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)]. The spraying operation was stopped when the specified amount 882 g of the film coating liquid had been sprayed, and then drying was carried out in the granulator for 10 minutes. The resulting granules were sieved through a #35 circular sieve (420 µm) and a #60 circular sieve (250 µm) to provide 1964 g of enteric coated and mannitol coated granules having a core.

The average particle diameter of the obtained granules was 333.7 µm.

Film coating liquid:

Mannitol	180 g
Purified water	1080 g

(5) Production of mixed powders

To 270 g of the above enteric coated and mannitol coated granules having a core were added 204.0 g of mannitol, 30 g of low-substituted hydroxypropyl cellulose LH-33 (hydroxypropoxyl group contents: 5.8 weight %), 30 g of crystalline cellulose [CEOLUS KG-801 (trade name), manufactured by Asahi Chemical Co., Ltd. (Japan)], 15 g of crospovidone, 3 g of citric acid anhydrous, 9 g of aspartame, 6 g of magnesium stearate and 3 g of flavor [STRAWBERRY DURAROME (trade name), manufactured by

Nihon Filmeneh Co., Ltd. (Japan)], which was admixed in a bag to give mixed powders.

(6) Production of orally disintegrable tablets

570 g of the above mixed powders were tabletted using Autograph (trade name; compressing force measurement apparatus) with a punch having a beveled edge, 13 mm in diameter, at a tableting pressure of 1.5 ton/cm², to provide tablets each weighing 570 mg.

The hardness and oral disintegration time of each tablet thus obtained were 2.6 kg and 20 seconds, respectively.

10 The acid-resistance of the obtained tablet was 3.5 %.

Example 3

A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.6 g of voglibose, 410.4 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8 % by weight, average particle diameter: 17.8 µm), 30.0 g of CEOLUS KG-801 [manufactured by Asahi Chemical Industry Co., Ltd. (Japan)], 30 g of crospovidone, 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tableting machine at the tableting pressure of 1.0 ton/cm² to provide tablets each weighing 300 mg.

The hardness and oral disintegration time of each tablet thus obtained were 10.7 kg and 26 seconds respectively.

25 Example 4

A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.6 g of voglibose, 440.4 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8 % by weight, average particle diameter: 17.8 µm),

30.0 g of crospovidone, 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tableting machine at the tableting pressure of 1.0 ton/cm² to provide tablets each weighing 300 mg.

The hardness and oral disintegration time of each tablet thus obtained were 7.1 kg and 20 seconds respectively.

Example 5

A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.4 g of voglibose, 470.6 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.7 % by weight, average particle diameter: 30.8 µm), 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powders was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tableting machine at the tableting pressure of 1.25 ton/cm² to provide tablets each weighing 300 mg.

The hardness and oral disintegration time of each tablet thus obtained were 4.5 kg and 23 seconds respectively.

Example 6

A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.4 g of voglibose, 470.6 g of mannitol [manufactured by Merck Japan Co., Ltd.], 120.0 g of low-substituted hydroxypropylcellulose LH-23 (content of hydroxypropoxyl group: 5.7 % by weight, average particle diameter: 30.8 µm), 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tableting machine at the tableting pressure of 1.25 ton/cm² to provide tablets each weighing 300 mg.

The hardness and oral disintegration time of each tablet thus obtained were 4.3 kg and 27 seconds respectively.

Example 7

A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 40.0 g of manidipine hydrochloride, 460.94 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 60.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8 % by weight, average particle diameter: 17.8 μm), 30.0 g of crospovidone, 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water in which was dissolved 0.06 g of yellow iron oxide. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tableted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tableting machine at the tableting pressure of 1.0 ton/cm² to provide tablets each weighing 300 mg.

The hardness and oral disintegration time of each tablet thus obtained were 6.0 kg and 21 seconds respectively.

Test Example 1

Low-substituted hydroxypropylcellulose LH-30 (content of hydroxypropoxyl group: 14.6 % by weight, average particle diameter: 17.26 μm), LH-31 (content of hydroxypropoxyl group: 11.0 % by weight, average particle diameter: 18.18 μm), LH-32 (content of hydroxypropoxyl group: 8.8 % by weight, average particle diameter: 17.57 μm) and LH-33 (content of hydroxypropoxyl group: 5.8 % by weight, average particle diameter: 17.8 μm) were administered to 4 females respectively, and dissolubility and taste were evaluated.

The results are shown in [Table 1].

[Table 1]

Low-substituted hydroxypropylcellulose	Trial subject	Evaluation
LH-30	4/4	difficult of dissolution in the oral cavity
LH-31	4/4	dissolved in the oral cavity, chalky taste
LH-32	4/4	dissolved in the oral cavity, chalky taste
LH-33	4/4	dissolved in the oral cavity, no chalky taste

As shown in [Table 1], dissolubility and chalky taste are improved, and further no roughness was felt, with respect to the case of low-substituted hydroxypropylcellulose LH-33 comprising 5.8 % by weight of hydroxypropoxyl group.

5 Test Example 2

Tablets were produced by using low-substituted hydroxypropylcellulose LH-30 (content of hydroxypropoxyl group: 14.6 % by weight, average particle diameter: 17.26 μm), LH-31 (content of hydroxypropoxyl group: 11.0 % by weight, average particle diameter: 18.18 μm), LH-32 (content of hydroxypropoxyl group: 8.8 % by weight, average particle diameter: 17.57 μm) and LH-33 (content of hydroxypropoxyl group: 5.8 % by weight, average particle diameter: 17.8 μm) in accordance with the following manner.

A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 398.5 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)] and 100 g of low-substituted hydroxypropylcellulose, and granulation was carried out while spraying purified water. After drying, 1.5 g of magnesium stearate was incorporated. The resulting powder was tableted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tableting machine at the tableting pressure of 1.0 ton/cm^2 to provide tablets each weighing 300 mg.

The resulting tablets were administered to 4 females respectively, and dissolubility and taste was evaluated.

The results are shown in [Table 2].

[Table 2]

Low-substituted hydroxypropylcellulose	Trial subject	Evaluation
LH-30	4/4	not dissolved in the oral cavity
LH-31	4/4	not dissolved in the oral cavity
LH-32	4/4	felt adhesiveness in the oral cavity, still chalky taste after dissolution
LH-33	4/4	rapidly dissolved in the oral cavity, a little chalky taste

As shown in [Table 2], dissolubility and chalky taste are improved, and further no roughness was felt, with respect to the case of low-substituted hydroxypropylcellulose LH-33 comprising 5.8 % by weight of hydroxypropoxyl group.

5 EFFECTS OF INVENTION

The rapidly disintegrable solid preparation of the present invention is usable for treatment and prevention of various kinds of diseases especially as the oral rapidly disintegrable solid preparation, which is capable of being administered to elders or children without water, because the preparation has superior disintegrability and
10 dissolubility. It is also improved in its disintegrability in the stomach.

And, the rapidly disintegrable solid preparation has superior long-term stability because the preparation has suitable strength.

Further, the rapidly disintegrable solid preparation of the present invention is improved in dissolubility and chalky taste, and has no roughness.

CLAIMS

1. A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group.
5
2. A preparation of Claim 1, which is an orally rapidly disintegrable solid preparation.
3. A preparation of Claim 1 or 2, which is a tablet.
4. A preparation of Claim 1, wherein the sugar is a sugar alcohol.
- 10 5. A preparation of Claim 4, wherein the sugar alcohol is mannitol or erythritol.
6. A preparation of Claim 1, wherein the sugar is in an amount of 5 to 97 parts by weight per 100 parts by weight of the solid preparation.
7. A preparation of Claim 1, wherein the low-substituted
15 hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group is used in an amount of 3 to 50 parts by weight per 100 parts by weight of the solid preparation.
8. A preparation of Claim 1, wherein the pharmacologically active ingredient is lansoprazole.
- 20 9. A preparation of Claim 1, wherein the pharmacologically active ingredient is voglibose.
10. A preparation of Claim 1, wherein the pharmacologically active ingredient is manidipine hydrochloride.
11. A preparation of Claim 1, wherein the pharmacologically active ingredient
25 is pioglitazone hydrochloride.
12. A preparation of Claim 1, wherein the pharmacologically active ingredient is candesartan cilexetil.
13. A preparation of Claim 3 which comprises fine granules.
14. A preparation of Claim 13, wherein the pharmacologically active

ingredient is comprised in fine granules of the solid preparation.

15. A preparation of Claim 14, wherein (i) a sugar and (ii) a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group are comprised in the solid preparation separately from fine
5 granules.

16. A preparation of Claim 15, wherein the sugar is in an amount of 5 to 97 parts by weight per 100 parts by weight of the rest of the solid preparation other than the fine granules.

17. A preparation of the Claim 15, wherein the low-substituted
10 hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group is in an amount of 3 to 50 parts by weight per 100 parts by weight of the rest of the solid preparation other than the fine granules.

18. Use of a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than 7 % by weight of hydroxypropoxyl group for producing a rapidly
15 disintegrable solid preparation comprising a pharmacologically active ingredient and a sugar.

19. A method for improving fast disintegrability of a solid preparation comprising a pharmacologically active ingredient and a sugar which is characterized in that a low-substituted hydroxypropylcellulose having 5 % by weight or more to less than
20 7 % by weight of hydroxypropoxyl group is contained therein.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 99/04015

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 98 53798 A (TAKEDA CHEMICAL INDUSTRIES, LTD.) 3 December 1998 (1998-12-03) the whole document	1-19
A	EP 0 839 526 A (TAKEDA CHEMICAL INDUSTRIES, LTD) 6 May 1998 (1998-05-06) cited in the application pages 6-8, comparative examples 3-5	1-19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 November 1999

Date of mailing of the international search report

19/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 99/04015

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9853798 A	03-12-1998	AU 7451198 A JP 11043429 A	30-12-1998 16-02-1999
EP 839526 A	06-05-1998	CA 2219705 A CN 1181237 A JP 10182436 A US 5958453 A	30-04-1998 13-05-1998 07-07-1998 28-09-1999